直接口服抗凝药治疗房颤颅内事件有效性与安全性的系统评价与Meta分析
该系统评价与Meta分析纳入92项观察性研究、107项比较,评估DOACs与VKAs在非瓣膜性房颤中缺血性卒中、血栓栓塞及颅内出血风险。结果显示不同DOAC之间及与VKA相比在上述结局上存在显著差异。
要点
- 阿哌沙班较达比加群降低卒中风险(HR 0.82,95%CI 0.68-0.99)。
- 达比加群、利伐沙班、阿哌沙班较VKA均降低TE/卒中风险。
- 阿哌沙班与利伐沙班较达比加群颅内出血风险更高。
核心结论
- 不同DOAC之间及与VKA相比,缺血性卒中、TE/卒中及ICH风险存在显著差异。
研究设计与样本
- 系统检索Medline和Embase至2021年4月,纳入观察性研究,提取风险比(HR)及95%置信区间(CI),采用随机效应模型。
- 共纳入92项研究,进行107项比较。
主要发现
- 阿哌沙班较达比加群降低卒中风险(HR 0.82,95%CI 0.68-0.99)。
- 利伐沙班较VKA降低卒中风险(HR 0.90,95%CI 0.83-0.98)。
- 达比加群(HR 0.85,95%CI 0.80-0.91)、利伐沙班(HR 0.83,95%CI 0.77-0.89)、阿哌沙班(HR 0.75,95%CI 0.65-0.86)较VKA降低TE/卒中风险。
- 阿哌沙班(HR 1.32,95%CI 1.03-1.68)和利伐沙班(HR 1.58,95%CI 1.31-1.89)较达比加群增加ICH风险。
- 达比加群(HR 0.48,95%CI 0.44-0.52)、阿哌沙班(HR 0.60,95%CI 0.49-0.73)、利伐沙班(HR 0.73,95%CI 0.65-0.81)较VKA降低ICH风险。
临床怎么用
- 临床选择DOAC时需综合评估卒中与颅内出血风险,不同DOAC的风险特征存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Observational studies have investigated the effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial fibrillation. We performed a systematic review and meta-analysis assessing the risk of ischaemic stroke, thromboembolism (TE) and intracranial haemorrhage (ICH) associated with the use of DOACs and VKAs. METHODS: Medline and Embase were systematically searched until April 2021. Observational studies were gathered and hazard ratios (HRs) with 95% confidence intervals (CI) were extracted. Subgroup analyses based on DOAC doses, history of chronic kidney disease, stroke, exposure to VKA, age and sex were performed. A random-effects model was used. RESULTS: We included 92 studies and performed 107 comparisons. Apixaban was associated with lower risk of stroke (HR: 0.82, 95% CI: 0.68-0.99) compared to dabigatran. Rivaroxaban was associated with lower risk of stroke (HR: 0.90, 95% CI: 0.83-0.98) compared to VKA. Dabigatran (HR: 0.85, 95% CI: 0.80-0.91), rivaroxaban (HR: 0.83, 95% CI: 0.77-0.89) and apixaban (HR: 0.75, 95% CI: 0.65-0.86) were associated with lower risk for TE/stroke compared to VKA. Apixaban (HR: 1.32, 95% CI: 1.03-1.68) and rivaroxaban (HR: 1.58, 95% CI: 1.31-1.89) were associated with higher risk of ICH compared to dabigatran. Dabigatran (HR: 0.48, 95% CI: 0.44-0.52), apixaban (HR: 0.60, 95% CI: 0.49-0.73) and rivaroxaban (HR: 0.73, 95% CI: 0.65-0.81) were associated with lower risk of ICH compared to VKA. CONCLUSION: Our study demonstrated significant differences in the risk of ischaemic stroke, TE/stroke and ICH associated with individual DOACs compared to both other DOACs and VKA.
引用
- Archontakis-Barakakis P, Li W, Kalaitzoglou D, et al. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies. Br J Clin Pharmacol. 2022. PMID: 35853612. doi:10.1111/bcp.15464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。